Patents by Inventor Blaine Bueche
Blaine Bueche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230293540Abstract: Devices, formulations, compositions, and methods are provided for inhibiting an inflammatory ophthalmic disease or eye condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor II inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory ophthalmic disease or condition in the patient’s eye(s). The therapeutic composition may be formulated for delivery to the patient by via injection, an implant, an eye drop, an emulsion, a suspension, an ointment, a nanomicelle, a nanoparticle, a nanosuspension, a liposome, an in-situ gel, a contact lens, or a microneedle or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.Type: ApplicationFiled: March 6, 2023Publication date: September 21, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Margaret Wong, Blaine Bueche
-
Publication number: 20230165874Abstract: Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.Type: ApplicationFiled: January 27, 2023Publication date: June 1, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Blaine Bueche
-
Publication number: 20220249618Abstract: Provided herein are pharmaceutical compositions comprising exenatide and an aqueous buffer, wherein the pharmaceutical compositions are packaged for administration via inhalation. Methods for treating diabetes mellitus are also described.Type: ApplicationFiled: July 1, 2020Publication date: August 11, 2022Inventors: Blaine BUECHE, Mei-chang KUO, John PATTON, Ian CHAN, Benjamin STEDMAN
-
Patent number: 11096990Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.Type: GrantFiled: October 23, 2018Date of Patent: August 24, 2021Assignee: AERAMI THERAPEUTICS, INC.Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
-
Publication number: 20210228824Abstract: A wicking member and methods of use of the same are disclosed herein. The wicking member can be a component of a medication inhaler. The medication inhaler can include a reservoir bowl defining a reservoir wherein a volume of liquid can be received. The reservoir bowl can include a top, a bottom, and a wall extending from the top to the bottom of the reservoir bowl. The medication inhaler can further include a wicking member proximate to the wall. The wicking member can extend along the wall at least partially from the top of the reservoir bowl to the bottom of the reservoir bowl. The wicking member can wick liquid to the bottom of the reservoir bowl.Type: ApplicationFiled: January 29, 2020Publication date: July 29, 2021Inventors: Ryan Patton, Benjamin Stedman, Blaine Bueche, John Patton
-
Patent number: 11065151Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: GrantFiled: December 18, 2020Date of Patent: July 20, 2021Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20210113374Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: ApplicationFiled: December 18, 2020Publication date: April 22, 2021Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Patent number: 10874548Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: GrantFiled: May 26, 2017Date of Patent: December 29, 2020Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Patent number: 10842951Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.Type: GrantFiled: October 23, 2018Date of Patent: November 24, 2020Assignee: Aerami Therapeutics, Inc.Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
-
Publication number: 20190343768Abstract: A dry powder insulin formulation for reconstitution including insulin, a buffering agent, and a salt. The dry powder insulin formulation includes between about 70 and 95% w/w of insulin, between about 5 and 30% w/w of the buffering agent, and less than about 1% w/w of the salt. The dry powder insulin formulation has less than about 5% water content.Type: ApplicationFiled: May 14, 2019Publication date: November 14, 2019Inventors: Blaine Bueche, Matthew Sander, Mei-chang Kuo
-
Publication number: 20190160153Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.Type: ApplicationFiled: October 23, 2018Publication date: May 30, 2019Applicant: Dance BioPharm, Inc.Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
-
Publication number: 20190054259Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.Type: ApplicationFiled: October 23, 2018Publication date: February 21, 2019Applicant: Dance BioPharm, Inc.Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
-
Patent number: 9968603Abstract: Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.Type: GrantFiled: March 14, 2014Date of Patent: May 15, 2018Assignee: FORSIGHT VISION4, INC.Inventors: Irina Astafieva, Judit Horvath, Kathleen Cogan Farinas, Blaine Bueche, Signe Erickson
-
Publication number: 20170258634Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20160243199Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.Type: ApplicationFiled: December 21, 2015Publication date: August 25, 2016Applicant: Dance BioPharm, Inc.Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
-
Publication number: 20140276482Abstract: Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Irina Astafieva, Judit Horvath, Kathleen Cogan Farinas, Blaine Bueche, Signe Erickson
-
Publication number: 20140031769Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: ApplicationFiled: November 18, 2011Publication date: January 30, 2014Applicant: ForSight Vision4, Inc.Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela MacFarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20110171312Abstract: Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Applicant: Nektar TherapeuticsInventors: Mei-Chang Kuo, Blaine Bueche, Mary J. Bossard, Cindy L. Barnes
-
Publication number: 20060018840Abstract: An aerosolizable formulation comprises free-base nicotine, an organic acid, and a hydrofluoroalkane propellant. The organic acid is present in a mole ratio with said nicotine in a range of about 0.25:1 (organic acid:nicotine) to about 4:1 (organic acid:nicotine). The organic acid and said free-base nicotine form a nicotine salt. An equivalent mixture of free-base nicotine and organic acid in water has a pH between about pH 3.0 and about pH 9.0. The aerosolizable formulation is aerosolizable, for example, by a metered dose inhaler for administration to a user.Type: ApplicationFiled: June 28, 2005Publication date: January 26, 2006Applicant: Nektar TherapeuticsInventors: David Lechuga-Ballesteros, Mei-Chang Kuo, Yuan Song, Blaine Bueche
-
Publication number: 20050152848Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.Type: ApplicationFiled: November 2, 2004Publication date: July 14, 2005Inventors: John Patton, Mei-Chang Kuo, J. Harris, Chester Leach, Kimberly Perkins, Blaine Bueche